



Brilliance in photodynamic technology™

Results for the third quarter 2010

# Photocure ASA

The world leader in photodynamic technology

27 October 2010



## Highlights for the third quarter 2010

(2009 figures in brackets)

- License agreement for Lumacan™ signed with Salix Pharmaceuticals in October
- Positive results from interim analysis of phase II study published on Cevira™
- Hexvix end user sales Year-to-date growing 32%
- Total revenues of NOK 11.4 million (NOK 12.5 million)
- Operating loss of NOK 15.9 million (NOK 12.2 million)
- Cash & cash equivalents of NOK 310.9 million per 30 September 2010

### Key figures

<i>NOK 000 (unaudited)</i>	Q3 10	Change	Q3 09	YTD 2010	Change	YTD 2009
Total revenues	11 363	-9 %	12 462	123 008	363 %	34 038
Gross profit	9 830	-10 %	10 893	117 413	385 %	30 391
R&D expenses	12 999	-23 %	16 957	52 260	9 %	47 873
Operating profit	-15 850	-29 %	-12 231	27 186	N/A	-49 036
Net profit	-11 568	N/A	355 337	34 810	-90 %	334 630
EPS, diluted (NOK)	-0.52		16.08	1.57		15.15

## Strategy

- Build a specialty pharma company
- Maximise the potential of the company's Photodynamic Technology Platform
- Leverage on experience to develop, register and commercialise new products in
  - Dermatology:
    - Continue the development of the dermatology portfolio, with Allumera and Visonac and other new dermatology products, and build a commercial platform in the US
  - Cancer:
    - Continue the commercialisation of Hexvix for bladder cancer diagnostics
    - Continue the development of the cancer portfolio and out-license prior to phase III studies

This strategy is based on a strong platform of intellectual property in photodynamic therapy.

## Operational review

### Global license agreement with Salix Pharmaceuticals for Lumacan™

Photocure signed a global agreement for development and commercialisation of Lumacan with Salix Pharmaceuticals, Inc. (NASDAQ:SLXP), a US specialty pharmaceutical company focused on gastrointestinal disease, on 20 October 2010. Lumacan is a photodynamic colorectal diagnostic intended to significantly improve the detection of precancerous and cancerous lesions in the colon through fluorescence diagnosis.

Under the agreement, Salix obtain an exclusive worldwide license to Lumacan excluding the Nordic region. Photocure received a signing fee of USD 4 million and is entitled to receive additional milestone payments totalling up to USD 126.5 million. These milestones relate to development and regulatory events as well as specific sales achievements. In addition to the milestones, Salix will pay Photocure tiered double digit royalties on net sales in the US and a significant percentage of all Salix sublicense revenue outside the US. Salix will control and cover development, registration and commercialisation costs for Lumacan worldwide, with Photocure covering certain costs of formulation development up to USD 3 million.

Photocure has retained the rights to market and sell Lumacan in the Nordic countries. In addition to the development of Lumacan for colorectal cancer, Salix has the exclusive right to explore and develop products for additional indications involving the diagnosis of gastrointestinal dysplasia and cancer. Payments for products in respect of any such additional indications will be negotiated if and when new product development is initiated.

### Hexvix® - Europe

#### Revenues from sales of Hexvix in Europe

<i>figures in NOK '000</i>	<b>Q3 2010</b>	<i>Change</i>	Q3 2009	<b>YTD 2010</b>	<i>Change</i>	YTD 2009
Own sales	<b>4.0</b>	-15%	4.7	<b>14.3</b>	9%	13.1
Partner sales	<b>7.4</b>	-5%	7.7	<b>25.3</b>	21%	21.0
<b>Total revenue</b>	<b>11.4</b>	-9%	12.5	<b>39.6</b>	16%	34.0

Hexvix is marketed by Photocure in the Nordic region and by GE Healthcare, the company's commercial partner, outside the Nordic region.

Sales revenues for Hexvix amounted to NOK 11.4 million (12.5) in the third quarter 2010, whereas sales through GE Healthcare accounted for NOK 7.4 million (7.7) and Photocure's own sales in the Nordic region were NOK 4.0 million (4.7). Sales in units from GE Healthcare to end-users increased by 30% from 5,376 units in third quarter 2009 to 6,991 units in the third quarter this year. The discrepancy between end-user sales and sales revenues relates to reduced inventory levels of Hexvix at GE Healthcare and unfavourable exchange rate development.

Sales for the first nine months of the year were NOK 39.6 million (34.0), representing an increase of 16.2% since last year.



In the Nordic region, the unit sales decreased by 6% from 1,226 in third quarter last year to 1,154 units this quarter. The decrease in the Nordic region was due to lower sales in Denmark and flat sales in the other Nordic countries.

### Hexvix® - USA

Cysview™ (the brand name for Hexvix in the US) received approval from FDA on 28 May 2010.

Photocure shipped the first order of 500 Cysview™ kits to GE Healthcare in the third quarter 2010. GE Healthcare, responsible for marketing and sales of Cysview in the US, and Karl Storz, responsible for marketing and sales of blue light cystoscopy equipment in the US, have signed a marketing agreement and will start establishing training centres for urologists in the fourth quarter 2010. Photocure expects FDA to approve an amendment to Karl Storz' PMA application in the fourth quarter 2010.

Photocure received EUR 7.5 million in milestone payment on October 13, 2010, and will receive the remaining EUR 2.5 million at the latest by the year end 2010.

### Progress in the clinical development programs

Photocure has a strong technology platform based on photodynamic therapy (PDT), the Photocure Technology Platform™, which provides a basis for the company's development projects.

	Indication	Status
Hexvix® /Cysview™	Detection of bladder cancer	Approved in EU/US
Allumera™	Improved facial skin appearance	Ongoing consumer trial
Visonac™	Treatment of moderate to severe acne	Phase II
Cevira™	Treatment of precursors of cervical cancer	Phase I/II
Lumacan™	Detection of colon cancer	Phase I/II

### Dermatology

Photocure's photodynamic technology is very well suited for the development of products that meet the needs to treat dermatological diseases. PDT is an established procedure in the dermatology field, and Photocure has been a leader in developing effective PDT products to serve that market. In addition, the technology offers opportunities to develop products for the large cosmetic and skin rejuvenation market.

In August, Photocure established a US subsidiary, Photocure Inc., and hired Terry Conrad to lead the company's US dermatology activities. Photocure is evaluating alternatives on how to market and sell its dermatology products in the US, i.e. through its own sales force and/or in collaboration with other US dermatology companies.

#### Visonac™ – treatment of moderate to severe acne

Photocure reported a 4<sup>th</sup> phase II study for Visonac in May 2010. The results of the study yielded an efficacy not as robust as the three previously reported phase II studies, and based on these results, Photocure started a small clinical study to optimize the application procedure. The study started in October 2010.



Photocure is also fielding a new round of market research for Visonac in order to investigate the proposed product positioning based on the current product profile. Following the results from these activities, Photocure will perform a phase IIb study in the US in 2011.

#### Allumera™ – A cosmetic product for improved facial skin appearance

Photocure started the development of Allumera, a cosmetic product for the dermatology market, in 2009. Allumera is built on the reported cosmetic improvements experienced with Photocure's divested cancer product Metvix/Aktilite. Today the cosmetic procedure market in US alone has an estimated value of USD 4 billion. Photocure's market research shows that the benefits observed with Allumera in the pilot trial offer advantages that will fit well within the current cosmetic procedures performed by dermatologists.

Photocure started a consumer trial (RevitAll™) for Allumera approved by the ethical committee (IRB) in April 2010. Results of the trial are expected during the first quarter 2011. Photocure has initiated a program of investigator studies (Glow™-program) done by leading dermatologists.

Photocure is working towards introduction of Allumera in the US in the first half of 2011.

#### **Cancer**

One of the major advantages of the Photocure Technology™ is its ability to treat and diagnose cancer precursors with a minimum of side effects. The products that are being developed meet the needs for early diagnosis and treatment of the diseases before they develop into more serious stages.

#### Cevira™ - Treatment of precursors for cervical cancer

Photocure is developing Cevira™ for the non-surgical treatment of cervical HPV infection and precancerous lesions of the cervix. Cevira™ is a photodynamic therapy that combines a drug formulation with a medical device and offers the potential for an easy, quick and safe treatment procedure for patients with mild cervical abnormalities.

Preliminary results from a multi-centre placebo controlled phase II study of 70 patients with mild cervical abnormalities was announced in October 2010. The results showed a three month response rate of 71% for Cevira™ compared to 43% in the control group. No serious side effects were reported. Cevira™ was administered as a vaginal suppository for five hours followed by photoactivation of 50J/cm<sup>2</sup> using a laser system. These results support the efficacy/clinical benefit of Cevira™ in patients with low-grade cervical lesions as the first therapeutic product in this field. The final six months follow up data will be made available the first quarter of 2011.

Photocure met with the FDA in October to discuss the development of Cevira. Based on these discussions, Photocure plans to submit a new IND to the FDA in the fourth quarter 2010 in order to position the product for review and approval as a fixed combination product and be able to start a Phase IIb study in EU and USA in beginning of 2011.

#### Lumacan™ - Diagnosis of colon cancer

Lumacan is being developed to increase the detection rate for polyps and colon cancer through fluorescence diagnosis. Colon cancer is traditionally diagnosed through colonoscopies (visual examination) with white light. However, it is increasingly being recognised that standard white-light colonoscopy has considerable limitations. The market for colonoscopies is growing as a result of extensive patient screening programs in Europe and USA.

Salix has, as of October 2010, taken over the responsibility to develop, register and commercialize Lumacan.

Photocure and Salix believe earlier detection and diagnosis of precancerous and cancerous lesions in the colon could ultimately lead to better targeted therapeutic care and increased colorectal cancer survival rates in patients. Lumacan is being developed for use in conjunction with standard white light colonoscopy diagnosis. Annually, approximately 14 million colonoscopies are performed in US. Lumacan will target high risk screening patients and diagnostic patients in follow-up of colon cancer. Collectively, these subgroups are estimated to be approximately 20% of total colonoscopies undertaken.

## Financial review

(Numbers in brackets are for the corresponding period in 2009)

The financial report per 30th of September 2010 has been prepared according to the IFRS (International Financial Reporting Standard) and follows the same principles as the Annual Report for 2009.

Photocure's divestment of Metvix/Aktelite in September 2009 changed the company's earnings profile. The 2009 accounts are adjusted for discontinued operations.

Sales revenues were NOK 11.4 million (12.5) in the third quarter 2010, representing a decrease of 9%. Sales revenues include royalties and sale of Hexvix kits to GE Healthcare and sale of Hexvix to the Nordic wholesalers. Royalties increased by 19% in line with the increase in end-user sales, adjusted for a weaker Euro to NOK. Hexvix was shipped to GE Healthcare in July and August, but not in September, due to new supply chain procedures.

For the first nine months of 2010, revenues amounted to NOK 123.0 million (34.0). This includes EUR 10.5 million in milestone revenues from GE Healthcare in 2010.

Research and development (R&D) expenses decreased by NOK 4.0 million to NOK 13.0 million (17.0) compared to the third quarter of 2009. A major part of the R&D decrease was related to lower level of clinical activities.

So far this year, dermatology R&D related to Visonac and Allumera account for NOK 21.5 million, and cancer R&D related to Hexvix, Lumacan and Cevira for NOK 25.0 million. NOK 2.3 million was spent on explorative research.

Marketing and sales (M&S) expenses increased by 98% to NOK 9.4 million (4.8) in the third quarter. For the first nine months of the year, M&S expenses were NOK 25.0 million (17.0), an increase of NOK 8.0 million. The increase is mainly due to increased activities in dermatology related to establishing the subsidiary in the US.

Operating loss was NOK 15.9 million (12.2) in the third quarter of 2010. The increase is mainly due to reduced revenues and increased expenses related to establishing the US operations.

Net financial items were NOK 4.3 million (1.6) in the third quarter of 2010 and NOK 7.6 million (1.1) in the first nine months of 2010.

Net loss for the third quarter of 2010 was NOK 11.6 million compared to a net profit of NOK 355.3 million in the third quarter of 2009. The net profit in the third quarter 2009 includes Photocure's divestment of Metvix/Aktelite.



Photocure is the largest shareholder in PCI Biotech Holding ASA (PCI Biotech) with 19.35% of the shares. The book value of the shareholding increased from NOK 11.5 million at 31 December 2009 to NOK 57.7 million at 30 September 2010, as the share price of the PCI Biotech share increased from NOK 11.00 to NOK 38.90 per share.

Total equity and liabilities for Photocure was NOK 500.0 million at the end of September 2010 compared to NOK 456.9 million at the end of 2009. Liquid funds amounted to NOK 310.9 million at the end of September 2009, compared to NOK 403.5 million at the end of 2009. Photocure received EUR 7.5 million in milestone payment on October 13, 2010, and will receive the remaining EUR 2.5 million at the latest by the year end. The decrease in cash in the first nine months of 2010 is due to a negative cash flow from operations of NOK 67.0 million.

Shareholders' equity was NOK 469.1 million, or 93.8%, at the end of the period, up from NOK 415.8 million, or 91.0%, at the end of last year.

Photocure bought 353,938 shares under its share repurchase program in the first nine months of 2010, for an average of NOK 47.07 per share. Photocure sold 112,019 own shares to employees in the same period, and owns 543,477 or 2.5% of the outstanding shares per 30 September 2010. The number of outstanding shares was 22,093,301 at the end of September 2010. The Board has decided to continue the share repurchase program.

## Subsequent events after the end of the quarter

On 4 October 2010, Photocure announced the preliminary clinical data after 4 months follow-up of the patients from the phase I/II study in Cevira.

On 5 October 2010, Photocure announced the publication in the highly ranked "Journal of Urology" of the phase III data for Hexvix. The data clearly documents reduced recurrence in bladder cancer patients after using Hexvix.

On 20 October 2010, Photocure announced the signing of a partnership agreement with Salix for Lumacan.

## Outlook

Photocure will have a strong focus on increasing the sales of Hexvix in Europe and to support a successful launch of Cysview in the US. End-user sales of Hexvix in Europe are expected to grow more than 30% in 2010.

Total expenses for 2010 are estimated to increase compared to 2009, in particular because of the increased activities in dermatology.

The Board of Directors  
Photocure ASA

Oslo, 26 October, 2010

The following unaudited information is presented according to IAS 34 - Interim Financial Reporting. The accounting policies adopted in this report are consistent with those followed in the preparation of the Group's annual financial statements for 2009 except that the presentation has adapted the new requirements in IAS 1 - Presentation of Financial Statements.

## Photocure ASA – Statement of comprehensive income

(all amounts in NOK 1,000 except per share data)

Q3 2010	Q3 2009		2010 1.1-30.9	2009 1.1-30.9	2009 1.1-31.12
11 363	12 462	Sales revenues	39 568	34 038	45 998
0	0	Signing fee and milestone revenues	83 440	0	0
<b>11 363</b>	<b>12 462</b>	<b>Total revenues</b>	<b>123 008</b>	<b>34 038</b>	<b>45 998</b>
-1 533	-1 569	Cost of products sold	-5 595	-3 647	-4 418
<b>9 830</b>	<b>10 893</b>	<b>Gross profit</b>	<b>117 413</b>	<b>30 391</b>	<b>41 580</b>
4 538	4 071	Other income	16 018	6 095	12 959
-1 924	-2 006	Indirect manufacturing expenses	-5 439	-6 158	-9 451
-12 999	-16 957	Research and development expenses	-52 260	-47 873	-73 800
-9 431	-4 775	Marketing and sales expenses	-24 999	-16 972	-24 984
-5 864	-3 457	Business development and administrative expenses	-23 547	-14 519	-25 256
<b>-15 850</b>	<b>-12 231</b>	<b>Operating profit/loss(-)</b>	<b>27 186</b>	<b>-49 036</b>	<b>-78 952</b>
4 492	2 649	Financial income	9 611	9 741	13 551
-210	-1 062	Financial expenses	-1 987	-8 620	-11 100
<b>4 282</b>	<b>1 588</b>	<b>Net financial profit/loss(-)</b>	<b>7 624</b>	<b>1 121</b>	<b>2 451</b>
<b>-11 568</b>	<b>-10 643</b>	<b>Profit/loss(-) before tax</b>	<b>34 810</b>	<b>-47 915</b>	<b>-76 501</b>
0	0	Tax expenses	0	0	0
<b>-11 568</b>	<b>-10 643</b>	<b>Net profit/loss(-)</b>	<b>34 810</b>	<b>-47 915</b>	<b>-76 501</b>
0	365 980	Discontinued operations (1)	0	382 545	388 883
<b>-11 568</b>	<b>355 337</b>	<b>Net profit/loss(-)</b>	<b>34 810</b>	<b>334 630</b>	<b>312 382</b>
-23 882	0	Other comprehensive income	28 760	1 048	4 192
<b>-35 450</b>	<b>355 337</b>	<b>Comprehensive income</b>	<b>63 570</b>	<b>335 678</b>	<b>316 574</b>
-0.53	16.08	Net profit/loss(-) per share, undiluted (2)	1.59	15.15	3.46
-0.52	16.08	Net profit/loss(-) per share, diluted (3)	1.57	15.15	3.46

(1) The Metvix/Aktelite business was sold in 3Q/09 and related revenues & expenses in this quarter are reclassified to Discontinued operations

(2) Undiluted net profit/loss per share is calculation based on average weighted number of shares outstanding.

(3) Diluted net profit per share is calculated adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares.





## Photocure ASA – Balance sheet

(all amounts in NOK 1,000)

	30.09.2010	30.09.2009	31.12.2009
<b>Non-current assets</b>			
Intangible assets, software	543	418	365
Machinery & equipment	1 685	526	1 772
Other investments (1)	69 427	8 384	14 585
<b>Total non-current assets</b>	<b>71 655</b>	<b>9 328</b>	<b>16 722</b>
<b>Current assets</b>			
Inventory	19 168	6 409	13 826
Receivables	98 256	400 384	22 811
Cash & cash equivalents	310 886	140 311	403 502
<b>Total current assets</b>	<b>428 310</b>	<b>547 105</b>	<b>440 140</b>
<b>Total assets</b>	<b>499 965</b>	<b>556 433</b>	<b>456 862</b>
<b>Equity and liabilities</b>			
<b>Equity</b>			
Share capital	11 047	11 047	11 047
Other paid-in capital	165 861	191 390	176 112
Retained earnings	292 193	323 061	228 624
<b>Shareholders' equity</b>	<b>469 101</b>	<b>525 497</b>	<b>415 783</b>
<b>Long-term liabilities</b>			
Other non-current liabilities	600	0	340
<b>Total long-term liabilities</b>	<b>600</b>	<b>0</b>	<b>340</b>
Current liabilities	30 264	30 936	40 739
<b>Total liabilities</b>	<b>30 864</b>	<b>30 936</b>	<b>41 079</b>
<b>Total equity and liabilities</b>	<b>499 965</b>	<b>556 433</b>	<b>456 862</b>

(1) Including shares in PCI Biotech Holding ASA at market value kNOK 57 701 as of 30.9.10 (kNOK 11 528 as of 31.12.09)



## Photocure ASA – Changes in equity

(all amounts in NOK 1,000)

Q3 2010	Q3 2009		2010 1.1-30.9	2009 1.1-30.9	2009 1.1.-31.12
503 239	181 864	<b>Equity at beginning of period</b>	<b>415 783</b>	<b>199 694</b>	<b>199 694</b>
0	-12 617	Net assets, discontinued	0	-12 617	0
0	0	Share buy back, net	-13 955	0	-15 989
0	0	Dividend	0	0	-87 950
1 313	914	Share-based compensation	3 703	2 742	3 454
-35 450	355 337	Comprehensive income	63 570	335 678	316 574
<b>469 101</b>	<b>525 497</b>	<b>Equity at end of period</b>	<b>469 101</b>	<b>525 497</b>	<b>415 783</b>

## Photocure ASA – Cash flow Statement

(all amounts in NOK 1,000)

Q3 2010	Q3 2009		2010 1.1-30.9	2009 1.1-30.9	2009 1.1.-31.12
-11 568	355 337	Profit/loss(-) before tax	34 810	334 630	312 382
278	384	Depreciation and amortisation	821	1 186	1 451
1 313	914	Share-based compensation	3 703	2 742	3 454
-3 252	-1 721	Net interests	-7 489	-6 333	-9 258
0	0	Write down financial assets	0	4 192	4 192
-5 755	-366 755	Changes in working capital	-90 311	-381 960	7 899
-2 885	215	Other operational items	-8 543	215	-2 674
<b>-21 869</b>	<b>-11 626</b>	<b>Net cash flow from operations</b>	<b>-67 008</b>	<b>-45 329</b>	<b>317 445</b>
1 905	1 384	Cash flow from investments	-11 654	5 747	10 104
0	-2	Cash flow from capital transactions	-13 955	-3	-103 944
<b>-19 964</b>	<b>-10 244</b>	<b>Net change in cash during the period</b>	<b>-92 617</b>	<b>-39 586</b>	<b>223 605</b>
330 849	150 556	Cash & cash equivalents at beginning of period	403 502	179 897	179 897
<b>310 885</b>	<b>140 311</b>	<b>Cash &amp; cash equivalents at end of period</b>	<b>310 885</b>	<b>140 311</b>	<b>403 502</b>



## Photocure ASA – Segment information

(all amounts in NOK 1,000)

3Q 2010 (Amounts in NOK 1000)	Cancer				Derm.(2)	Total	% vs. PY
	Own	Partner	R&D(1)	Sum			
Sales Hexvix	4 002	7 361	0	11 363	0	11 363	-9 %
Cost of goods sold	-327	-1 206		-1 533		-1 533	-2 %
<b>Gross profit</b>	<b>3 675</b>	<b>6 155</b>	<b>0</b>	<b>9 830</b>	<b>0</b>	<b>9 830</b>	<b>-10 %</b>
Gross profit %	92 %	84 %	0	87 %	0	87 %	
Milestone revenues	0	0	0	0	0	0	
MAL/Metvix/Aktilite revenues (3)	0	0	0	0		3 222	
Operating expenses	-4 189	-3 250	-9 095	-16 535	-12 366	-28 901	25 %
<b>Operating profit</b>	<b>-515</b>	<b>2 905</b>	<b>-9 095</b>	<b>-6 705</b>	<b>-12 366</b>	<b>-15 850</b>	
Net finance						4 282	
<b>Profit before tax</b>	<b>-515</b>	<b>2 905</b>	<b>-9 095</b>	<b>-6 705</b>	<b>-12 366</b>	<b>-11 568</b>	
<b>3Q 2009 (Amounts in NOK 1000)</b>							
	Cancer				Derm.(2)	Total	
	Own	Partner	R&D(1)	Sum			
Sales Hexvix	4 716	7 746	0	12 462	0	12 462	
Cost of goods sold	-214	-1 355	0	-1 569	0	-1 569	
<b>Gross profit</b>	<b>4 502</b>	<b>6 391</b>	<b>0</b>	<b>10 893</b>	<b>0</b>	<b>10 893</b>	
Gross profit %	95 %	83 %		87 %		87 %	
Discontinued operations	0	0	0	0	0	365 980	
Operating expenses	-3 253	-1 509	-14 443	-19 205	-3 919	-23 124	
<b>Operating profit</b>	<b>1 249</b>	<b>4 882</b>	<b>-14 443</b>	<b>-8 312</b>	<b>-3 919</b>	<b>353 749</b>	
Net finance						1 588	
<b>Profit before tax</b>	<b>1 249</b>	<b>4 882</b>	<b>-14 443</b>	<b>-8 312</b>	<b>-3 919</b>	<b>355 337</b>	

(1) Including share of general and administrative expenses

(2) R&D Visonac/Allumera, Business development and Admin expenses. 2009 amounts includes R&D and personnel costs only.

(3) Deferred revenue from Metvix divestment, sale of MAL, returns and reimbursement of Metvix



1-3Q 2010 (Amounts in NOK 1000)							
	Cancer			Sum	Derm.(2)	Total	% vs. PY
	Own	Partner	R&D(1)				
Sales Hexvix	14 284	25 284	0	39 568	0	39 568	16 %
Cost of goods sold	-975	-4 620		-5 595		-5 595	53 %
<b>Gross profit</b>	<b>13 309</b>	<b>20 664</b>	<b>0</b>	<b>33 973</b>	<b>0</b>	<b>33 973</b>	<b>12 %</b>
Gross profit %	93 %	82 %	0	86 %	0	86 %	
Milestone revenues	0	83 440	0	83 440	0	83 440	
MAL/Metvix/Aktelite revenues (3)	0	0	0	0	0	10 749	
Operating expenses	-13 101	-11 059	-32 866	-57 026	-43 950	-100 976	27 %
<b>Operating profit</b>	<b>208</b>	<b>93 045</b>	<b>-32 866</b>	<b>60 387</b>	<b>-43 950</b>	<b>27 186</b>	
Net finance						7 624	
<b>Profit before tax</b>	<b>208</b>	<b>93 045</b>	<b>-32 866</b>	<b>60 387</b>	<b>-43 950</b>	<b>34 810</b>	
1-3Q 2009 (Amounts in NOK 1000)							
	Cancer			Sum	Derm.(2)	Total	
	Own	Partner	R&D(1)				
Sales Hexvix	13 065	20 973	0	34 038	0	34 038	
Cost of goods sold	-572	-3 075	0	-3 647	0	-3 647	
<b>Gross profit</b>	<b>12 494</b>	<b>17 898</b>	<b>0</b>	<b>30 391</b>	<b>0</b>	<b>30 391</b>	
Gross profit %	96 %	85 %		89 %		89 %	
Discontinued operations	0	0	0	0	0	382 545	
Operating expenses	-15 985	-7 702	-49 165	-72 852	-6 575	-79 427	
<b>Operating profit</b>	<b>-3 492</b>	<b>10 195</b>	<b>-49 165</b>	<b>-42 461</b>	<b>-6 575</b>	<b>333 509</b>	
Net finance						1 121	
<b>Profit before tax</b>	<b>-3 492</b>	<b>10 195</b>	<b>-49 165</b>	<b>-42 461</b>	<b>-6 575</b>	<b>334 630</b>	

(1) Including share of general and administrative expenses

(2) R&D Visonac/Allumera, Business development and Admin expenses. 2009 amounts includes R&D and personnel costs only.

(3) Deferred revenue from Metvix divestment, sale of MAL, returns and reimbursement of Metvix

**For more information, please contact:**

Kjetil Hestdal, President and CEO

Mobile: +47 913 19 535

E-mail: [kh@photocure.no](mailto:kh@photocure.no)

Christian Fekete, CFO

Mobile: +47 916 42 938

E-mail: [cf@photocure.no](mailto:cf@photocure.no)

Photocure ASA  
 Hoffsvveien 48  
 NO – 0377 Oslo  
 Norway

Telephone: +47 22 06 22 10

Fax: +47 22 06 22 18